+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07768345

Evaluating Safety and Immune Response of RSVpreF Vaccine Revaccination in Immunocompromised Adults

Led by Pfizer · Updated on 2026-10-14

440

Participants Needed

17

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and immune response to revaccination with the RSVpreF vaccine in immunocompromised adults aged 18 years and older. This phase 3 study aims to determine the best interval for revaccination by grouping participants based on their prior RSV vaccination history. Participants must be immunocompromised as defined by the study and have a life expectancy of at least 12 months. All participants will receive one dose of the RSVpreF vaccine in their arm. They will be assigned to one of four groups depending on their previous RSV vaccine exposure no prior vaccine, one dose about 1 year prior, one dose about 2 years prior, or two doses about 3 years prior. The study will last approximately 12 months during which participants will be followed to assess vaccine effects. During the study, participants will visit the clinical site at least four times for evaluations including monitoring for local and systemic reactions, adverse events, and any new chronic medical conditions. Blood samples will be collected before vaccination and at 1, 6, and 12 months afterward to measure immune responses against RSV types A and B. Safety and immune response data will be collected throughout the study to inform revaccination timing in this population.

CONDITIONS

Brief Title

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here